Back to Journals » Cancer Management and Research » Volume 14

The Overexpression of Kinesin Superfamily Protein 2A (KIF2A) Was Associated with the Proliferation and Prognosis of Esophageal Squamous Cell Carcinoma [Retraction]

Authors Li D, Sun H, Meng L, Li D

Received 3 March 2022

Accepted for publication 3 March 2022

Published 7 March 2022 Volume 2022:14 Pages 981—982

DOI https://doi.org/10.2147/CMAR.S364909



Li D, Sun H, Meng L, Li D. Cancer Manag Res. 2020;12:3731–3739

The Editor and Publisher of Cancer Management and Research wish to retract the published article. Concerns were raised following a request from the authors to replace in vivo and immunohistochemistry (IHC) images in Figure 4 due to the authors having lost the original data and being unable to verify the findings as reported. The authors could not provide a satisfactory explanation for how their repeated experiments supported the original findings, given the original data was no longer available. In addition, the animal ethics approval documents provided by the authors for the original study were not satisfactory. The findings of the article were deemed unreliable, and the Editor requested for the article to be retracted.

Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.

This retraction relates to this paper

Creative Commons License © 2022 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.